RxDoctor Payments Data

Douglas Federman, MD

Internal Medicine · Toledo, OHNPI 1427043629

Payments from drug & device makers

$2,249in general payments, 2019–2025

Across 49 payments — averaging $45.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$893
  • AstraZeneca$267
  • Novartis$212
  • Pulmonx Corporation$125
  • Urovant Sciences Inc$125
  • Bayer$118
  • plus $509 from 12 others

What the payments were for

  • Travel & lodging$67130%
  • Food & beverage$1,57870%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,249 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$58,884
Medicare patients
251
Services billed
707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide92$97,526
EliquisApixaban41$44,335
JanuviaSitagliptin Phosphate22$29,083
OzempicSemaglutide19$25,560
FarxigaDapagliflozin Propanediol22$21,922
JardianceEmpagliflozin11$17,799
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,235
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$11,325
Breo ElliptaFluticasone/Vilanterol14$7,044
Atorvastatin Calcium535$5,701
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,831
Incruse ElliptaUmeclidinium Bromide11$3,831
SymbicortBudesonide/Formoterol Fumarate13$3,301
Albuterol Sulfate HfaAlbuterol Sulfate106$3,194
Pantoprazole Sodium200$2,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$31$97,52692 claims
Novo NordiskOzempic$118$25,56019 claims
AstraZenecaFarxiga, Symbicort$267$25,22335 claims
Boehringer IngelheimJardiance$20$17,79911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →